摘要
目的分析表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)药物相互作用相关性不良反应的发生情况及特点,为安全用药提供参考。方法检索中国知网(CNKI)、维普中文科技期刊数据库(VIP)、万方数据库和PubMed数据库关于EGFR-TKI药物相互作用相关性不良反应的个案报道进行文献分析。结果检索出EGFR-TKI药物相互作用相关性不良反应个案报道13篇共13例患者,男4例,女9例,年龄35~79岁,平均年龄56岁。13例患者中,均为第1代EGFR-TKI药物为主(吉非替尼6例、厄洛替尼6例、埃克替尼1例)。与EGFR-TKI相互作用的药物品种较多,其中抗凝药物居第1位(6例)。不良反应累及血液系统、神经系统、泌尿系统、肝胆系统、皮肤及其附件系统等多个器官/系统。结论临床医师和药师应知晓有临床意义的EGFR-TKI药物相互作用,加强用药监测,避免和减少用药风险。
Objective To analyze adverse drug reactions(ADRs)associated with drug interactions of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI),and to provide references for safe medication use.Methods Case reports on ADRs related to EGFR-TKI drug interactions were retrieved from the CNKI,VIP,Wanfang,and PubMed databases for literature analysis.Results A total of 13 case reports involving 13 patients with ADRs associated with EGFR-TKI drug interactions were identified.Of these 13 patients,4 were male and 9 were female,with age from 35 to 79 years,and the average age was 56 years.All 13 cases of ADRs associated with drug interactions with the first generation EGFR-TKI included gefitinib(n=6),erlotinib(n=6),and icotinib(n=1).A variety of drugs interacted with EGFR-TKI,with anticoagulant drugs being the most common(n=6).Adverse reactions involved multiple organs/systems including the hematologic,nervous,urinary,hepatobiliary,skin,and appendages systems.Conclusions Clinicians and pharmacists should be aware of these clinically significant drug interactions with EGFR-TKI and avoid the combination therapy.It is necessary to strengthen monitoring and intervention to reduce and avoid the risk of medication.
作者
程军
韩一萱
汪龙
张冠军
赵丹
CHENG Jun;HAN Yixuan;WANG Long;ZHANG Guanjun;ZHAO Dan(Department of Pharmacy,the Third People's Hospital Bengbu City,Anhui Province,Bengbu 233000,China)
出处
《医药导报》
北大核心
2026年第2期307-311,共5页
Herald of Medicine
基金
2023年度蚌埠市级科技创新指导类项目(20230117)。
关键词
表皮生长因子受体酪氨酸激酶抑制剂
药物相互作用
不良反应
文献分析
Epidermal growth factor receptor tyrosine kinase inhibitor
Drug interactions
Adverse drug reactions
Literature analysis
